Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio (Nasdaq: VOR) announced inducement grants on April 1, 2026 for nine newly hired employees: 42,650 stock options and 9,050 RSUs under the 2023 Inducement Plan.

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) announced inducement grants on April 1, 2026 for nine newly hired employees: 42,650 stock options and 9,050 RSUs under the 2023 Inducement Plan.

The options carry a $17.39 exercise price (closing price on grant date), a 10-year term, and a four-year vesting schedule (25% after 12 months, then monthly). RSUs vest over four years with 25% after 12 months and quarterly thereafter, all subject to continued employment and award agreements.

Argus Apr 2 session

+3.80% close to close Open Argus

Details

News Market Reaction – VOR

On Apr 2, the first trading day after this news, VOR closed 3.80% above the previous close.

Data tracked by StockTitan Argus for the Apr 2 session.

Key Figures

Current share price: $17.39 Stock options granted: 42,650 shares RSUs granted: 9,050 shares +5 more

Current share price

$17.39

Closing price used as stock option exercise price on grant date

Stock options granted

42,650 shares

Inducement grant to new employees under 2023 Inducement Plan

RSUs granted

9,050 shares

Restricted stock units as inducement awards to new employees

New employees

9 employees

Recipients of stock options and RSUs as material inducements

Option term

10 years

Duration of stock options granted under Inducement Plan

Initial vesting cliff

25% after 12 months

Applies to both options and RSUs, subject to continued employment

Option vesting tail

36 months monthly

Remaining stock options vest monthly over following 36 months

RSU vesting tail

36 months quarterly

Remaining RSUs vest quarterly over following 36 months

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Earnings and update

   24h Move

   +1.5%

   Q4 and 2025 results plus funding runway and Phase 3 development update.

2. Mar 30

   Clinical trial progress

   24h Move

   +1.5%

   First patient dosed in global Phase 3 UPSTREAM SjD telitacicept trial.

3. Mar 27

   Private placement

   24h Move

   +1.9%

   $75 million private placement at $14.05 per share with TCGX-led group.

4. Mar 23

   Inducement grants

   24h Move

   -4.3%

   Stock options and RSUs granted under 2023 Inducement Plan to new hires.

5. Feb 23

   Conference participation

   24h Move

   +13.8%

   Participation and presentation at the 46th Annual TD Cowen Health Care Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, stock options

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"stock options to purchase an aggregate of 42,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 9,050 shares of Vor Bio’s common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

The stock options have a ten-year term, and an exercise price of $17.39 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vor Bio (VOR) grant on April 1, 2026 to new employees?

Vor Bio granted 42,650 stock options and 9,050 RSUs to nine new hires. According to the company, the awards were inducements under the 2023 Inducement Plan and subject to award agreements and vesting conditions.

What is the exercise price and term of the VOR stock options granted April 1, 2026?

The options have an exercise price of $17.39 and a 10-year term. According to the company, $17.39 equals Vor Bio's closing stock price on the grant date and options expire ten years from grant.

How do the VOR option vesting schedules work for the April 1, 2026 grants?

Options vest over four years: 25% after 12 months, then monthly for 36 months. According to the company, vesting is contingent on continued employment and governed by the award agreement and Inducement Plan.

What is the RSU vesting schedule for Vor Bio's April 1, 2026 grants?

RSUs vest over four years with 25% after 12 months and the remainder vesting quarterly over 36 months. According to the company, RSU payouts depend on continued employment and the terms of the award agreement.

Under which plan were Vor Bio's April 1, 2026 inducement grants made (VOR)?

The grants were made under the Vor Biopharma 2023 Inducement Plan as Nasdaq Rule 5635(c)(4) inducements. According to the company, the awards comply with Nasdaq listing rule requirements for new-hire inducements.

How many employees received inducement equity from Vor Bio (VOR) on April 1, 2026?

Nine newly hired employees received inducement awards on April 1, 2026. According to the company, those nine hires collectively received 42,650 options and 9,050 RSUs under the Inducement Plan.